Effect of transglutaminase on Aβ1-40 fibril formation and neurotoxicity

Alzheimer's Reports

Volumn 2, Issue 3, 1999, Pages 165-170

  Yatin, Servet M ^a   Aksenova, Marina ^a   Aksenov, Michael ^a   Allan Butterfield, D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001556842     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aksenov MY, Aksenova MV, Butterfield DA et al. (1996). Glutamine synthetase-induced enhancement of β-amyloid peptide Aβ(1-40) neurotoxicity accompanied by abrogation of fibril formation and Aβ fragmentation. Neurochem 66, 2050-2056.
2. Aksenova MV, Aksenov MY, Butterfield DA and Carney JM (1996). α1-Antichymotrypsin interactions with Aβ(1-40) inhibits fibril formation but does not affect the peptide toxicity. Neuroscience Lett 211, 45-48.
3. Ambron RT and Kremzner LT (1982). Post-translational modification of neuronal proteins: evidence fortransglutaminase activity in R2, the giant cholinergic neuron of aplysia. Proc Natl Acad Sci USA 79, 3442-3446.
4. Brewer GJ, Torricelli JR, Evege EK and Price PJ (1993). Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 35, 567-576.
5. Butterfield DA (1997) β-Amyloid associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10, 495-506.
6. Castano ME, Prelli F, Wisniewski HM et al. (1995). Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. Biochem J 306, 599-604.
7. Chang SK and Chung SI (1986) Cellular transglutaminase. The particulate-associated transglutaminase from chondrosarcoma and liver: partial purification and characterization. J Biol Chem 261, 8112-8121.
8. Cooper AJ, Sheu KF, Burke JR et al. (1999). Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. J Neurochem 72, 889-899.
9. Dudek SM and Johnson GV (1993). Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of τ. J Neurochem 61, 1159-1162.
10. Dudek SM and Johnson GV (1994). Transglutaminase facilitates the formation of polymers of the β-amyloid peptide. Brain Res 651, 129-133.
11. El Alaoui S, Mian S, Lawry J et al. (1992). Cell cycle kinetics, tissue transglutaminase and programmed cell death (apoptosis). FEBS Lett. 311, 174-178.
12. Eriksson S, Janciauskiene S and Lannfelt L (1995). α1-antichymotrypsin regulates β amyloid peptide fibril formation. Proc Natl Acad Sci USA 92, 18210-18217.
13. Folk JE and Finlayson JS (1977). The ε-(γ-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 31, 1-133.
14. Folk JE (1980). Transglutaminases. Ann Rev Biochem 49, 517-531.
15. Fraser PE, Nguyen JT, McLachlan DR et al. (1993). α 1-antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 61, 298-305.
16. Gilad GM and Varan LE (1985). Transglutaminase activity in rat brain: characterization, distribution, and changes with age. J Neurochem 45, 1522-1526.
17. Gilad GM, Varon LE and Gilad VH (1985). Calcium-dependent transglutaminase of rat sympathetic ganglion in development and after nerve injury. Neurochem. 44, 1385-1390.
18. Giordano T, Pan JB, Monteggia LM et al. (1994). Similarities between β amyloid peptides (1-40) and (40-1 ) effect on aggregation, toxicity in vitro, and injection in young and rats. Exp Neurobiol 125, 175-182.
19. Hand D, Perry MJ and Haynes LW (1993). Cellular transglutaminases in neural development. Intl J Dev Neurosci 11, 709-720.
20. Ho GJ, Gregory EJ, Smirnova IV et al. (1994). Cross-linking of β-amyloid protein precursor catalyzed by tissue transglutaminase. FEBS Lett 349, 151-154.
21. Ikura K, Takahata K and Sasaki R (1993). Cross-linking of a synthetic partial-length (1-28) peptide of the Alzheimer β/A4 amyloid protein by transglutaminase. FEBS Lett 326, 109-111.
22. Itchinose A, Bottenus RE and Davie EW (1990). Structures of transglutaminases. J Biol Chem 265, 13411-13414.
23. Johnson GV, Cox TM, Lockhart JP et al. (1997). Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 751, 323-329.
24. Maccioni RB and Seeds NW (1986). Transglutaminase and neuronal differentiation. Mol Cell Biochem 69, 161-168.
25. Murphy S, Huang CC, Lajevardi N et al. (1994). Effect of hypoxia and reoxygenation on the activity of transglutaminase in brain of newborn piglets. Neurosci Lett 172, 42-46.
26. Murthy SN, Wilson JH, Lukas TJ et al. (1998). Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase. J Neurochem 71, 2607-2614.
27. Nordstedt C, Naslund J, Tjernberg LO et al. (1994). The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils. J Biol Chem 269, 30773-30776.
28. Oda T, Wals P, Osterbund H et al. (1995). Clusterin (ApoJ) alters the aggregation of amyloid β-peptide Aβ(1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp Neurol 136, 22-31.
29. Pike CJ, Walencewicz AJ, Kosmoski J et al. (1995). Structure-activity analyses of β-amyloid peptides: contributions of the Aβ 25-35 region to aggregation and neurotoxicity. J Neurochem 64, 253-265.
30. Rasmussen LK, Sorensen ES, Petersen TE et al. (1994). Identification of glycine and lysine residues in Alzheimer amyloid β/A4 peptide responsible for transglutaminase-catalyzed homopolymerization and crosslinking to α2M receptor. FEBS Lett 338, 161-166.
31. Selkoe DJ, Abraham C and Ihara Y (1982). Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc Natl Acad Sci USA 79, 6070-6074.
32. Shearman MS, Hawtin SR and Tailor VJ (1995). The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides. J Neurochem 68, 218-227.
33. Snyder SW, Ladror US, Wadw GT et al. (1994). Aβ aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain length. Biophys J 67, 1216-1228.
34. Yatin SM, Aksenov MY and Butterfield DA (1999). The antioxidant vitamin E modulates amyloid β-peptide induced creatine kinase activity inhibition and increased protein oxidation: Implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 24, 427-435.
35. Zhang W, Johnson BR, Suri DE et al. (1998). Immunohistochemical demonstration of tissue transglutaminase in amyloid plaques. Acta Neuropathol 96, 395-400.